




PHARMACEUTICAL 2019

ATHERSYS INC NEW
Rank 166 of 363





PHARMACEUTICAL 2019

ATHERSYS INC NEW Rank 166 of 363



The relative strengths and weaknesses of ATHERSYS INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATHERSYS INC NEW compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 40% points. The greatest weakness of ATHERSYS INC NEW is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 75% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	57,840
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,475
Liabilities, Non-Current	0
Other Assets	888
Other Compr. Net Income	-24,283
Other Expenses	855
Other Liabilities	0
Other Net Income	1,379
Other Revenues	24,291
Property and Equipment	3,002
Research and Development	38,656
Selling, General and Administrative Expense	10,442

Output Variable	Value in 1000 USD
Assets	61,730
Liabilities	15,475
Expenses	49,953
Revenues	24,291
Stockholders Equity	46,255
Net Income	-24,283
Comprehensive Net Income	-36,424
Economic Capital Ratio	112%